Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AC Immune S.A. (NQ: ACIU ) 3.480 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 3.480 Bid (Size) 3.430 (2) Ask (Size) 3.480 (1) Prev. Close 3.480 Today's Range 3.480 - 3.480 52wk Range 2.200 - 5.140 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 July 16, 2024 From AC Immune SA Via GlobeNewswire RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 14, 2024 Via Benzinga Performance YTD -25.80% -25.80% 1 Month -14.07% -14.07% 3 Month +43.80% +43.80% 6 Month -14.07% -14.07% 1 Year +17.17% +17.17% More News Read More Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday May 31, 2024 Via Benzinga AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 May 28, 2024 From AC Immune SA Via GlobeNewswire Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 31, 2024 Via Benzinga e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday May 23, 2024 Via Benzinga DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session May 15, 2024 Via Benzinga ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024 May 13, 2024 Via InvestorPlace Gold Down Over 1%; AC Immune Shares Spike Higher May 13, 2024 Via Benzinga Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? May 13, 2024 Via Benzinga Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session May 13, 2024 Via Benzinga Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge May 13, 2024 Via Benzinga Exposures Fossil Fuels Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? May 13, 2024 Via InvestorPlace Why Is Safe & Green Development (SGD) Stock Down 5% Today? May 13, 2024 Via InvestorPlace Topics Regulatory Compliance Exposures Legal Regulatory Why Is AC Immune (ACIU) Stock Up 45% Today? May 13, 2024 Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday May 13, 2024 Via InvestorPlace AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update May 13, 2024 From AC Immune SA Via GlobeNewswire AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease May 13, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease May 13, 2024 From AC Immune SA Via GlobeNewswire ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023 March 14, 2024 Via InvestorPlace AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update March 14, 2024 From AC Immune SA Via GlobeNewswire AC Immune Announces Upcoming Presentations at AD/PD™ 2024 February 22, 2024 From AC Immune SA Via GlobeNewswire AC Immune to Regain Global Rights to Crenezumab and Semorinemab January 22, 2024 From AC Immune SA Via GlobeNewswire AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases January 03, 2024 From AC Immune SA Via GlobeNewswire AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial December 15, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.